Carlos Estebas-Armas

Carlos Estebas-Armas

Auto-generated profile, based on publicly available information

Carlos Estebas-Armas


Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 April 2026 in JMIR Preprints
Verified
Preprint
Open access
CECarlos Estebas-Armas
Carlos Estebas-Armas
AMAlejandro Medina-López
Alejandro Medina-López
DBDaniel Blanco-De-Miguel
Daniel Blanco-De-Miguel
ILItsaso Losantos-García
Itsaso Losantos-García
MHMaría Hernández-Barral
María Hernández-Barral
ÁMÁngel Martín-Montes
Ángel Martín-Montes
BACKGROUND Discriminating mild cognitive impairment (MCI) from subjective cognitive decline (SCD) and healthy controls (HC) remains challenging. Digital tools can overcome classic paper-and-pencil test limitations, offering sensitive and engaging screening for early cognitive impairment. OBJECTIVE To evaluate the diagnostic accuracy of CogniPaz, an ecologically oriented, tablet-based, gamified cognitive assessment tool composed of nine tasks designed to evaluate memory and executive functions, in discriminating MCI from SCD and HC. METHODS This prospective observational study recruited participants with cognitive complaints and HC at La Paz University Hospital Cognitive Impairment Unit (April 2025–January 2026). Following clinical and Montreal Cognitive Assessment (MoCA) evaluations, participants were classified into HC (no cognitive complaints, MoCA≥26), SCD (cognitive complaints, MoCA≥26), and MCI (cognitive complaints without functional impairment, MoCA<26; subdivided into amnestic [aMCI] and non-amnestic phenotypes). An evaluator blinded to MoCA results oversaw the automated, self-administered CogniPaz assessment (including automatic timing). Receiver operating characteristic (ROC) analyses (with age-adjusted models compared via DeLong's test) evaluated diagnostic accuracy, Spearman assessed CogniPaz-MoCA correlation, and a 0-9 scored questionnaire measured CogniPaz usability. A subset of participants with available biomarker data underwent an exploratory analysis to assess the tool's capacity to distinguish biologically confirmed neurodegeneration suggestive of Alzheimer Disease (AD). RESULTS Participants (N=84; median age: 72.0 years) included HC (n=27; 74.0), SCD (n=17; 59.0), and MCI (n=40; 74.0) groups, the latter subclassified into aMCI (n=22; 76.5) and non-amnestic MCI (n=18; 71.5). The aMCI group was significantly older than the SCD group (P=.003). The median administration time for CogniPaz was 9.39 minutes (IQR 7.53–11.38). CogniPaz scores correlated strongly with MoCA (r=.81, 95% CI .75-.89, P<.001). CogniPaz achieved high diagnostic accuracy, independently of age: MCI vs HC (AUC=0.880, 95% CI 0.798-0.961), MCI vs SCD (AUC=0.915, 95% CI 0.841-0.990), aMCI vs HC (AUC=0.910, 95% CI 0.830-0.990), and aMCI vs SCD (AUC=0.943, 95% CI 0.878-1.000). It showed capacity for detecting biologically confirmed neurodegeneration (n=39, AUC=0.810, 95% CI 0.661-0.958). At the<28.5 points cutoff, sensitivity ranged from 85.0% to 90.9% and specificity from 74.1% to 82.4% across comparisons. Particularly, it was accurate in differentiating aMCI vs SCD (90.9% sensitivity, 82.4% specificity). User satisfaction was high (median 8.4/9). CONCLUSIONS CogniPaz showed good capacity to differentiate MCI/aMCI from SCD and HC, and appears promising for identifying AD-related neurodegeneration, with a strong correlation with MoCA score and good patient acceptance. These results support its use as a digital screening tool for early-stage cognitive impairment. External, multi-centre longitudinal validation is essential before considering its implementation in primary care settings.

4 November 2026 in JMIR mHealth and uHealth
Verified
Journal Article
Open access
CECarlos Estebas-Armas
Carlos Estebas-Armas
AMAlejandro Medina-López
Alejandro Medina-López
DBDaniel Blanco-De-Miguel
Daniel Blanco-De-Miguel
IGItsaso Losantos García
Itsaso Losantos García
MHMaría Hernández-Barral
María Hernández-Barral
ÁMÁngel Martín-Montes
Ángel Martín-Montes
Background: Discriminating mild cognitive impairment (MCI) from subjective cognitive decline (SCD), and healthy controls (HC) remains challenging. Digital tools may overcome paper-and-pencil screening’s limitations. Objective: This study evaluated the diagnostic accuracy and usability of CogniPaz (Daniel Blanco), an ecologically oriented, mobile health (mHealth), gamified cognitive assessment tool exploring memory and executive functions, in discriminating MCI (particularly amnestic phenotypes [aMCI]) from SCD, and HC. Methods: This prospective observational study recruited a convenience sample of consecutive patients with cognitive complaints and HC at La Paz University Hospital Cognitive Disorders Unit from April 2025 to January 2026. Demographic and clinical characteristics, and Montreal Cognitive Assessment (MoCA) scores were collected. An evaluator blinded to the MoCA scores oversaw the automated, self-administered CogniPaz assessment. Participants were classified into HC (no cognitive complaints, MoCA score≥26), SCD (cognitive complaints, MoCA score≥26), and MCI (cognitive complaints without functional impairment, MoCA score<26, subdivided into amnestic [aMCI] and nonamnestic phenotypes). Receiver operating characteristic (ROC) analyses using age-adjusted models, the DeLong test, and bootstrap validation evaluated diagnostic accuracy across groups. The correlation between MoCA and CogniPaz scores was assessed using Spearman rank correlation. Participants with available biomarker data underwent exploratory analysis of CogniPaz’s ability to detect biologically confirmed any-cause neurodegeneration (bND). Usability was tested using an ad hoc Likert questionnaire (1‐9 points). Results: The participants (n=84, 57.1% female; median age 72.0, IQR 62.5-77.0 years) included 27 HC, 17 with SCD, 22 with aMCI, and 18 with nonamnestic MCI. The aMCI group was older than the SCD group (age: median 76.5, IQR 70.8-78.8 vs median 59.0, IQR 50.0-69.0 years; Kruskal-Wallis/Dunn, P =.003). CogniPaz scores correlated with MoCA scores (ρ = 0.81, 95% CI 0.75‐0.89; P< .001). CogniPaz showed good concurrent accuracy, independently of age: MCI vs HC (area under the curve [AUC]=0.880, 95% CI 0.798‐0.961), MCI vs SCD (AUC=0.915, 95% CI 0.841‐0.990), aMCI vs HC (AUC=0.910, 95% CI 0.830‐0.990), and aMCI vs SCD (AUC=0.943, 95% CI 0.878‐1.000). At the provisional <28.5 cutoff point, sensitivity ranged from 85.0% (34/40, 95% CI 70.2‐94.3) to 90.9% (20/22, 95% CI 70.8‐98.9) and specificity from 74.1% (20/27, 95% CI 53.7‐88.9) to 82.4% (14/17, 95% CI 56.6‐96.2) across comparisons. CogniPaz suggested capacity to detect bND (AUC=0.810, 95% CI 0.661‐0.958), with potential incremental value over MoCA and age (odds ratio [OR]=0.78, 95% CI 0.60‐0.94; P =.02). Median administration time was 9.39 (IQR 7.53‐11.38) minutes with 100% (84/84) completion. User satisfaction was high (median score 8.4/9, IQR 7.9‐8.6; Cronbach α=0.84). Conclusions: CogniPaz is an innovative, user-friendly mHealth tool that addresses classical cognitive screening tools’ limitations through a brief, multidomain, minimally supervised gamified format, with high patient acceptance. It correlates with MoCA scores, shows good concurrent capacity to differentiate MCI, particularly aMCI, from SCD and HC, and appears promising for identifying bND. Pending external longitudinal validation, these findings support CogniPaz as a candidate for early cognitive screening in primary care.